Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.

Ferrandina G, Salutari V, Vincenzi B, Marinaccio M, Naglieri E, Loizzi V, Carpano S, Amadio G, Tonini G, Scambia G, Lorusso D.

Gynecol Oncol. 2013 Sep;130(3):505-10. doi: 10.1016/j.ygyno.2013.06.008. Epub 2013 Jun 14.

PMID:
23774301
2.

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.

Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME.

Br J Cancer. 2007 Dec 17;97(12):1618-24. Epub 2007 Nov 13.

3.

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'ó E, Colombo N.

J Clin Oncol. 2005 Mar 20;23(9):1867-74.

4.

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D.

Lung Cancer. 2012 Jun;76(3):354-61. doi: 10.1016/j.lungcan.2011.12.002. Epub 2011 Dec 23.

PMID:
22197612
5.

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.

del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gómez J, Parekh T, Park YC, McMeekin S.

Med Oncol. 2013 Mar;30(1):435. doi: 10.1007/s12032-012-0435-1. Epub 2013 Feb 9.

PMID:
23397080
6.

Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.

Nicoletto MO, Baldoni A, Casarin A, Randon G, Nardin M, Baretta Z, Lardelli P, Nieto A, Alfaro V, Rigamonti C, Conte PF.

Tumori. 2015 Sep-Oct;101(5):506-10. doi: 10.5301/tj.5000371. Epub 2015 Jun 18.

7.

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

Schmitt T, Keller E, Dietrich S, Wuchter P, Ho AD, Egerer G.

Mar Drugs. 2010 Oct 13;8(10):2647-58. doi: 10.3390/md8102647.

8.

Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.

McMeekin DS, Lisyanskaya A, Crispens M, Oza AM, Braly P, Doering D, Bayever E, Michiels B, Markman M.

Gynecol Oncol. 2009 Aug;114(2):288-92. doi: 10.1016/j.ygyno.2009.04.034. Epub 2009 May 23.

PMID:
19476988
9.

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.

Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, Favis R, Ricci D, Poveda A.

Ann Oncol. 2015 May;26(5):914-20. doi: 10.1093/annonc/mdv071. Epub 2015 Feb 26.

10.

Trabectedin for the treatment of relapsed ovarian cancer.

Papaioannou D, Rafia R, Stevenson MD, Stevens JW, Evans P.

Health Technol Assess. 2011 May;15 Suppl 1:69-75. doi: 10.3310/hta15suppl1/08. Review.

11.

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study.

Ferrandina G, Corrado G, Mascilini F, Malaguti P, Samaritani R, Distefano M, Masciullo V, Di Legge A, Savarese A, Scambia G.

BMC Cancer. 2014 Dec 13;14:947. doi: 10.1186/1471-2407-14-947.

12.

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, Poveda A, Boman K, Westermann AM, Lebedinsky C; Yondelis Ovarian Cancer Group.

Ann Oncol. 2009 Nov;20(11):1794-802. doi: 10.1093/annonc/mdp198. Epub 2009 Jun 25.

13.

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM.

J Clin Oncol. 2010 Jul 1;28(19):3107-14. doi: 10.1200/JCO.2009.25.4037. Epub 2010 Jun 1.

14.

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.

Simpson EL, Rafia R, Stevenson MD, Papaioannou D.

Health Technol Assess. 2010 May;14 Suppl 1:63-7. doi: 10.3310/hta14Suppl1/09. Review.

15.

Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.

Fayette J, Boyle H, Chabaud S, Favier B, Engel C, Cassier P, Thiesse P, Méeus P, Sunyach MP, Vaz G, Ray-Coquard I, Ranchère D, Decouvelaere AV, Alberti L, Pérol D, Blay JY.

Anticancer Drugs. 2010 Jan;21(1):113-9. doi: 10.1097/CAD.0b013e328333057b.

PMID:
19887935
16.

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.

Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, Casali PG, Balaña C, Schöffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD.

Eur J Cancer. 2012 Nov;48(16):3036-44. doi: 10.1016/j.ejca.2012.05.012. Epub 2012 Jun 29.

PMID:
22749255
17.

Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.

Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, Dei Tos AP, Raspagliesi F, Judson I, Casali PG.

Gynecol Oncol. 2011 Dec;123(3):553-6. doi: 10.1016/j.ygyno.2011.08.016. Epub 2011 Sep 13.

PMID:
21917307
18.

Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.

Belli C, Piemonti L, D'Incalci M, Zucchetti M, Porcu L, Cappio S, Doglioni C, Allavena P, Ceraulo D, Maggiora P, Dugnani E, Cangi MG, Garassini G, Reni M.

Cancer Chemother Pharmacol. 2016 Mar;77(3):477-84. doi: 10.1007/s00280-015-2932-3. Epub 2015 Dec 14.

PMID:
26666646
19.

Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.

Paz-Ares L, Rivera-Herreros F, Díaz-Rubio E, García M, Casado E, Cubedo R, Gravalos C, Alfaro V, Gómez J, Izquierdo MA, Tabernero J.

Clin Colorectal Cancer. 2007 May;6(7):522-8.

PMID:
17553201
20.

Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.

Colombo N.

Int J Gynecol Cancer. 2011 May;21 Suppl 1:S12-6. doi: 10.1097/IGC.0b013e318217b321. Review.

PMID:
21540666
Items per page

Supplemental Content

Write to the Help Desk